放射性药物治疗诊断学市场报告：2030 年趋势、预测与竞争分析

放射性药物治疗治疗诊断学趋势与预测

到 2030 年，全球放射性药物治疗治疗诊断学市场预计将达到 39 亿美元，2024 年至 2030 年复合年增长率为 11.2%。该市场的主要驱动因素是癌症发生率的增加和心血管疾病治疗中应用的增加。全球放射性药物治疗诊断学市场的未来前景广阔，医院、诊断影像中心和学术/研究机构市场都有机会。

Lucintel 预测 PET 示踪剂将在预测期内达到最高成长。

由于技术先进的系统的可用性和医院数量的不断增加，预计医院仍将是该市场中最大的部分。

由于慢性病的增加、放射性药物和宠物扫描仪的容易取得，预计北美在预测期内将出现最高的成长。

放射性药物治疗治疗诊断学市场的新趋势

随着诊断和治疗技术的进步，放射性药物治疗诊断学市场正在迅速发展。结合诊断和治疗的治疗诊断学在个人化医疗中越来越重要，尤其是在肿瘤学中。该市场的新兴市场趋势反映了放射性药物开发、监管发展以及针对各种疾病状态的扩大应用的创新。这些趋势支持在技术进步和研发投资增加的推动下转向更有针对性和更有效的治疗方法。

• 标靶治疗和诊断的整合：放射性药物中诊断和治疗的整合是一个重要趋势。这种整合将能够透过放射性标记化合物精确靶向癌细胞，从而改善诊断和治疗。该领域的治疗进展使肿瘤可视化和治疗同时实现，从而实现更个人化和有效的治疗计划。该公司正在开发新型放射性药物，可以识别特定的生物标记并提供有针对性的放射治疗，从而显着改善患者的治疗效果并减少副作用。
• 扩大放射性核种的选择：除了碘 131 等传统放射性核种之外，市面上用于治疗诊断学的放射性核种日益多样化。镏-177和锕-227等新型放射性核种由于其良好的崩坏特性和治疗各种癌症的有效性而受到关注。这些放射性核素可提高靶向性、提高成像品质并降低毒性。扩大放射性核种的选择有助于开发更有效、更安全的放射性药物，扩大可治疗疾病的范围并改善治疗结果。
• 放射性标记生物分子的进展：人们对用于治疗诊断应用的放射性标记生物分子（例如抗体、胜胜肽和小分子）越来越感兴趣。放射性标记的生物分子可以特异性结合癌细胞和其他疾病标靶，从而实现精确成像和标靶治疗。该领域的创新促进了新型放射性药物的开发，提高了诊断准确性和治疗效果。研究重点是优化标记技术并增强这些生物分子的稳定性和标靶化能力，以推进治疗诊断学领域的发展。
• 个人化医疗方法的发展：个人化医疗对放射性药物治疗诊断学市场的影响越来越大。透过根据个别患者资料（包括遗传和分子资讯）量身订做治疗，治疗诊断学变得更加精确。基因组学和分子诊断学的进步使得识别放射性药物可靶向的特定生物标记成为可能。这种方法确保根据患者独特的疾病特征量身定制治疗，提高疗效，最大限度地减少副作用，并促进更个人化的治疗策略的发展趋势。
• 增加投资和合作：放射性药物治疗诊断学领域的投资和合作显着增加。製药公司、生技公司和研究机构正在合作加速新型放射性药物的开发，并更有效地将其推向市场。合作研究着重于临床试验、监管核准和技术进步。研发投资正在推动创新、扩大放射性药物产品线并促进整体市场成长。这一趋势预示着该细分市场的蓬勃发展和未来突破的潜力。

由于技术进步和投资增加，放射性药物治疗诊断学市场正在经历重大变革时期。标靶治疗和诊断的整合、放射性核素的多样化、放射性标记生物分子的开发、个人化医疗方法以及活性化的投资和合作等主要趋势正在重塑这一格局。这些趋势反映了人们对精准医学的日益重视以及更有效和个人化治疗的潜力不断增长，凸显了放射性药物治疗诊断学领域的动态性质。

放射性药物治疗治疗诊断学市场的最新趋势

放射性药物治疗诊断学市场的最新趋势反映了诊断和治疗工具融合以增强精准医疗的重大进展。由于技术创新、监管发展以及对个人化治疗方法的日益关注，结合诊断影像和标靶治疗的治疗诊断学正在迅速发展。这些发展正在改变我们诊断和治疗疾病（特别是癌症）的方式，并带来更有效和客製化的医疗解决方案。该市场的主要亮点是放射性核素应用、治疗学和合作研究的进步，这些进步共同改善了患者的治疗结果并扩大了治疗诊断应用的范围。

• FDA核准新型放射性药物：最近 FDA核准用于治疗神经内分泌肿瘤的新型放射性药物（例如 Lutathera）代表了治疗诊断学市场的重大发展。这些核准代表了标靶放射治疗的进步，并扩大了个人化癌症治疗的选择。精确瞄准特定肿瘤类型的能力可减少脱靶放射线并改善治疗效果。此类治疗的监管批准正在促进临床整合，扩大患者先进治疗的可用性，并促进治疗诊断学市场的成长。
• 新放射性核种的出现：锕227和铜64等新放射性核种的采用正在增强放射性药物在治疗诊断上的能力。这些放射性核素具有独特的崩坏特性，可以提高影像解析度和治疗效果。例如，actinium-227 用于靶向 α 疗法，可直接向癌细胞提供强大的辐射。这些新型放射性核种的开发和应用正在扩大放射性药物的治疗范围和功效，支持治疗诊断学市场的成长并扩大治疗选择。
• 放射性标记生物分子的进步：抗体和胜肽等生物分子放射性标记的进步正在推动治疗诊断学市场的创新。放射性标记的生物分子可以特异性靶向并结合疾病标记物，从而实现精确的成像和治疗。最近的趋势包括改进的标记方法以及开发具有更高亲和性和稳定性的新型生物分子。这些进步提高了诊断准确性和标靶治疗功效，使放射性标记生物分子成为个人化医疗的关键组成部分，并扩大了其临床应用。
• 个人化医疗的成长：向个人化医疗的转变正在对放射性药物治疗诊断学市场产生重大影响。个人化医疗根据个别患者的情况（包括遗传和分子资讯）客製化治疗方案。这一趋势正在推动放射性药物的发展，这些药物可以精确地针对每个患者的疾病特异性生物标记。透过整合遗传资料和放射性药物，医疗保健提供者可以提供更有效和个人化的治疗，改善患者的治疗结果并加速治疗诊断解决方案的采用。
• 增加产业合作和投资：放射性药物治疗诊断学市场的产业合作和投资正在显着增加。製药公司、生技公司和研究机构之间的合作正在加速新治疗药物和技术的开发。此次合作的重点是临床试验、监管核准和技术创新。增加投资支持研究和开发，从而引入先进的放射性药物并扩大治疗诊断应用。这一趋势凸显了市场的成长潜力以及对推动治疗和诊断解决方案的承诺。

放射性药物治疗诊断学市场的最新发展凸显了标靶治疗和诊断的重大进展。关键发展正在推动这一领域的进步，包括 FDA 对新药的核准、新放射性核素的出现、放射性标记生物分子的进步、个人化医疗的成长以及研究合作和投资的增加。这些进步提高了治疗精度，扩大了治疗选择，并有助于整个治疗诊断学市场的成长和发展，为更有效和个人化的医疗解决方案铺平了道路。

放射性药物治疗诊断学市场的策略性成长机会

由于诊断和治疗技术的创新，放射性药物治疗诊断学市场正在迅速发展。治疗诊断学将靶向成像和治疗结合起来，描述了精准医学中一个有前景的解决方案。随着市场的成长，一些关键应用正在呈现策略成长机会。这些机会反映了治疗诊断学可以显着增强患者照护，例如肿瘤学、循环系统和神经学。透过利用这些应用程序，相关人员可以推动创新、改善治疗结果并扩大市场范围。下面，我们概述了放射性药物治疗治疗诊断学市场中各种应用的五个关键成长机会。

• 肿瘤学：肿瘤学领域代表了放射性药物治疗治疗诊断学的主要成长机会。使用镏-177和锕-227等放射性药物开发的标靶治疗为多种癌症（包括前列腺癌和神经内分泌肿瘤）提供了精确的治疗选择。放射性标记抗体和胜肽的技术创新使得标靶治疗治疗辐射直接照射癌细胞，有望提高治疗效果并减少副作用。扩大标靶治疗的范围并提高其可用性将带来显着的市场成长并改善癌症治疗的患者预后。
• 神经病学：神经病学是放射性药物治疗治疗诊断学的新兴应用领域。用于神经影像学的放射性药物的开发以及阿兹海默症和帕金森氏症等神经系统疾病的标靶治疗代表了一个重大的成长机会。新的放射性追踪剂和治疗方法可以增强这些疾病的诊断和管理，提供更准确的影像和标靶治疗选择。该领域的创新将有助于改善早期诊断、疾病进展监测以及根据患者个别需求量身定制治疗，从而扩大神经病学放射性药物治疗诊断学市场。
• 心臟科 在心臟科中，放射性药物治疗有可能彻底改变心血管疾病的诊断和治疗。用于心臟影像成像的先进放射性示踪剂可提供有关心肌灌注和功能的详细信息，有助于管理冠状动脉疾病等疾病。此外，标靶放射治疗可能为心臟相关肿瘤提供新的治疗方法。用于心臟应用的创新放射性药物的开拓将提高诊断准确性和治疗效果，为心臟病学市场创造重大成长机会。
• 感染疾病：放射性药物在感染疾病的应用越来越受到人们的关注。放射性药物可透过针对特定病原体或发炎反应来精确成像和诊断感染疾病。此外，可以考虑标靶化放射线治疗来治疗某些感染疾病，例如对常规治疗方法有抗药性的细菌感染疾病。扩大该领域的研究和开发将为感染疾病管理带来新的诊断和治疗工具，从而促进放射性药物治疗诊断学市场的成长并改善患者照护。
• 个人化医疗：个人化医疗是放射性药物治疗治疗诊断学的主要成长机会。透过整合遗传和分子讯息，放射性药物可以针对与个别疾病相关的特定生物标记进行客製化。这种方法可以实现更精确、更有效的治疗，改善治疗结果并最大限度地减少副作用。基因分析和生物标记识别的进步正在促进客製化治疗诊断解决方案的开发，扩大个人化放射性药物市场并提高患者照护的准确性。

放射性药物治疗治疗诊断学市场的策略性成长机会涵盖多个关键应用，包括肿瘤学、神经病学、循环系统、感染疾病和个人化医疗。透过放射性药物技术和临床整合的进步，每种应用都为创新和扩展提供了独特的可能性。透过利用这些机会，相关人员可以提高治疗准确性，改善患者治疗结果，并推动治疗诊断学市场的持续成长。

治疗诊断学市场驱动因素与挑战

放射性药物治疗诊断学市场受到各种技术、经济和监管因素的显着影响。主要成长动力包括放射性药物技术的进步、对个人化医疗日益增长的需求以及支持性的法规环境。相反，高开发成本、监管障碍和供应链问题等挑战也会影响市场动态。对于希望利用治疗诊断学领域机会的相关人员来说，了解这些驱动因素和挑战至关重要。该分析强调了塑造市场的关键因素及其对未来成长的影响。

推动放射性药物治疗诊断学市场的因素是：

1.技术进步：放射性药物开发的技术进步是治疗诊断学市场的主要驱动因素。改进的放射性核种生产、先进的放射性标记技术和增强的成像技术等创新使诊断和治疗更加精确和有效。具有更好靶向性和更少副作用的新型放射性药物的开拓正在扩大治疗选择并增加市场需求。这些进步有助于制定个人化治疗计划，最终透过提供更量身定制和更有效的医疗解决方案来推动市场成长。

2.对个人化医疗的需求不断增长：对个人化医疗的日益重视正在对放射性药物治疗诊断学市场产生重大影响。个人化医疗方法利用遗传、分子和生物标记资讯来根据个别患者的情况量身订做治疗方案。这一趋势将促进放射性药物的开发，这些药物可以特异性针对独特的疾病标记物，从而实现更有效和个人化的治疗。随着个人化医疗需求的增加，对创新放射性药物的需求也在增加，从而推动了市场扩张和持续研发。

3.支持性法规环境：支持性法规环境是放射性药物治疗诊断学市场成长的关键驱动力。 FDA 和 EMA 等监管机构简化了放射性药物的核准流程，为新药推向市场提供了明确的途径。最近对新放射性药物的监管核准和临床试验指南的製定正在促进市场准入并鼓励投资。此类监管支持加速了创新放射性药物的开发和商业化，促进市场成长并扩大治疗选择。

4.增加研发投资：增加研发（R＆D）投资是推动治疗诊断学市场成长的关键因素。製药公司、生技公司和研究机构正在大力投资开发新的放射性药物和技术。这项投资支持新疗法、临床试验和技术创新的进展。研发资金的增加将透过加速采用新的治疗诊断解决方案、增加治疗选择、促进持续创新和扩大可用药物的管道来推动市场成长。

5.扩大在医疗领域的应用：放射性药物治疗治疗诊断学在肿瘤学、神经病学、循环系统和感染疾病等各个医疗领域的应用不断增加，正在推动市场成长。在不同治疗领域应用治疗诊断学的能力扩大了治疗选择并增加了市场潜力。随着放射性药物新适应症的确定和开发，市场对这些技术的需求和应用不断增加。这种扩张增强了整体市场前景，并记录了多个治疗领域的成长机会。

放射性药物治疗诊断学市场面临的挑战如下：

1.开发和生产成本高：开发和生产成本高：开发和生产成本高是放射性药物治疗诊断学市场的主要挑战。放射性药品的生产涉及放射性核种生产、放射性标记、品管等复杂流程，需要大量资金投入。这些高成本限制了新放射性药物的供应，并为中小企业进入市场设置了障碍。解决此类成本挑战对于确保更广泛的市场采用和维持该细分市场的永续性至关重要。

2. 监管障碍和核准流程：对于进入放射性药物治疗诊断学市场的公司来说，克服监管障碍和核准流程很困难。临床试验、安全性评估和监管核准的严格要求可能会延迟市场进入并延长开发时间。地区之间监管标准的差异进一步加剧了核准流程的复杂性。公司必须有效应对这些监管挑战，以成功地将新药推向市场并确保符合全球标准。

3. 供应链和分销问题：供应链和分销问题可能会影响放射性药物的可用性和市场成长。放射性药物的製造和分销通常很复杂，因为它们需要特殊的处理和储存条件。供应链中断，例如放射性核种製造的延迟或物流挑战，可能会影响向医护人员及时供应产品。解决这些供应链挑战对于确保产品稳定供应和满足市场需求至关重要。

放射性药物治疗诊断学市场受到多种因素的推动，例如技术开拓、对标靶治疗的需求不断增加、有利的市场政策、研发资金的增加以及更广泛的医学应用。然而，也存在需要考虑的重大障碍，例如开发成本高、监管困难和供应链困难。无论如何，为了使市场进一步发展和繁荣，相关人员认为这些都是为了利用现有的前景并解决治疗诊断学市场动态格局中存在的挑战，我必须解决一些问题。

放射性药物治疗诊断学领域预测

本研究按产品类型、来源、适应症、最终用途和地区提供了放射性药物治疗诊断学的全球预测。

放射性药物治疗诊断学市场的国家展望

随着诊断和治疗方法的整合改变了癌症治疗和个人化医疗，放射性治疗诊断学市场正在取得重大进展。美国、中国、德国、印度和日本等关键地区的最新进展反映了标靶治疗、创新放射性药物和临床应用的加强。这些发展凸显了精准医疗对于改善病患治疗效果和优化治疗效果日益重要。这些主要市场的最新发展如下。

• 美国：美国：在美国，由于标靶治疗和精准医学的进步，放射性药物治疗诊断学市场正在经历快速成长。主要进展包括 FDA核准新的放射性药物，例如用于神经内分泌肿瘤的 Lutathera 和扩大的放射性配体治疗选择。诊断影像和治疗能力的整合正在提高更准确地诊断和治疗癌症的能力。随着对研究和临床试验的大量投资以及製药公司和研究机构之间的合作，美国的技术创新正在加速，治疗诊断的应用范围正在扩大。
• 中国：随着中国对生物技术和医疗基础设施的大力投资，中国的放射性药物治疗诊断学市场正在扩大。最近的发展包括用于癌症治疗的放射性药物的生产和应用方面的进展，重点是发展国内製造能力和临床试验。中国也在加强个人化医疗的力度，一些新药正在进行临床试验，以提高诊断和治疗的准确性。中国政府对创新和医疗改革的支持正在推动先进放射性药物技术的采用，并促进市场的显着成长。
• 德国：德国专注于研发，处于放射性药物治疗诊断学市场创新的前沿。最近的进展包括采用新的放射性药物和治疗方法，例如前列腺癌的标靶放射治疗。德国强大的医疗保健系统以及学术机构和产业之间的合作正在推动治疗诊断学的进步。此外，我们也致力于先进诊断影像技术与放射性药物治疗的融合，以提高诊断准确性和治疗效果。德国在临床试验和监管核准的领先地位使其在全球市场中发挥重要作用。
• 印度：由于医疗基础设施的改善和医疗技术的投资，印度的放射性药物治疗诊断学市场正在成长。最近的发展包括推出新的放射性药物产品以及改善都市区和农村地区获得先进治疗的机会。印度研究机构和製药公司正在积极开发和测试新的治疗诊断药物。政府改善癌症护理和增加先进诊断和治疗方法选择的可用性的倡议正在推动市场成长。印度正致力于扩大其放射性药物生产和临床研究能力，为该领域的发展做出贡献。
• 日本：日本在放射性药物治疗诊断学市场取得了重大进展，特别是在新型放射性药物的开发和应用方面。最近的进展包括核准用于标靶癌症治疗的新型放射性药物和改进的成像技术。日本注重大学与工业界之间的研究与合作，以促进市场创新。此外，日本致力于将放射性药物方法整合到其医疗系统中，以增强精准医疗。日本在放射性药物生产和临床应用方面的进步正在推动成长，并将其定位为全球市场的主要参与企业。

常问问题

Q.1 放射性药物治疗诊断学的市场规模有多大？

答：到 2030 年，全球放射性药物治疗诊断学市场预计将达到 39 亿美元。

Q.2 放射性药物治疗诊断学市场的成长预测是多少？

答：2024年至2030年，全球放射性药物治疗诊断学市场预计将以11.2%的复合年增长率成长。

Q.3 影响放射性药物治疗诊断学市场成长的关键驱动因素有哪些？

答：这个市场的主要驱动因素是癌症盛行率的增加以及心血管疾病治疗中应用的增加。

Q4.市场的主要细分市场有哪些？

答：全球放射性药物治疗治疗诊断学市场的未来性广阔，医院、诊断影像中心和学术/研究机构市场充满机会。

Q5.市场上主要企业有哪些？

答：放射性药物治疗诊断学领域的主要企业有：

• Bayer
• GE Healthcare Technologies
• Curium
• Lantheus Medical Imaging
• Telix Pharmaceuticals
• Cardinal Health
• Advanced Accelerator Applications
• Jubilant Radiopharma
• Theragnostics
• Nuview Life Sciences

Q6.未来最大的细分市场是什么？

答案：Lucintel 预计 PET 示踪剂将在预测期内达到最高成长。

Q7. 预计未来五年哪个地区将成为最大的市场？

答：由于慢性病盛行率不断上升、放射性药物和宠物扫描仪易于取得，预计北美在预测期内将出现最高成长。

Q8. 可以客製化报告吗？

答：是的，Lucintel 列出了 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球放射性药物治疗诊断学市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球放射性药物治疗诊断学市场趋势（2018-2023）与预测（2024-2030）
• 按产品类型分類的全球放射性药物治疗诊断学市场
  • α发射体
  • β放射体
  • PET示踪剂
• 按来源分類的全球放射性药物治疗诊断学市场
  • 核子反应炉
  • 迴旋加速器
• 按适应症分類的全球放射性治疗诊断学市场
  • 肿瘤学
  • 心臟病学
  • 神经病学
  • 其他的
• 按最终用途分類的全球放射性药物治疗诊断学市场
  • 医院
  • 影像诊断中心
  • 学术研究所
  • 其他的

第四章 2018-2030年区域市场趋势及预测分析

• 全球放射性药物治疗诊断学市场区域分布
• 北美治疗诊断学市场
• 欧洲放射性药物治疗诊断学市场
• 亚太地区放射性药物治疗诊断学市场
• 其他地区的放射性药物治疗诊断学市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按产品类型分類的全球放射性药物治疗诊断学市场成长机会
  • 全球放射性药物治疗诊断学市场成长机会（按来源）
  • 按适应症分類的全球放射性治疗诊断学市场成长机会
  • 按最终用途分類的全球放射性药物治疗诊断学市场成长机会
  • 按地区分類的全球放射性治疗诊断学市场成长机会
• 全球放射性药物治疗诊断学市场的新兴趋势
• 战略分析
  • 新产品开发
  • 全球放射性药物治疗诊断学市场的产能扩张
  • 全球放射性药物治疗诊断学市场的合併、收购与合资企业
  • 认证和许可

第七章主要企业概况

• Bayer
• GE HealthCare Technologies
• Curium
• Lantheus Medical Imaging
• Telix Pharmaceuticals
• Cardinal Health
• Advanced Accelerator Applications
• Jubilant Radiopharma
• Theragnostics
• NuView Life Sciences

Radiopharmaceutical Theranostics Trends and Forecast

The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets. The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030 with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Within this market, hospitals will remain the largest segment due to availability of technologically advanced systems and rising number of hospitals.

North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Emerging Trends in the Radiopharmaceutical Theranostics Market

The radiopharmaceutical theranostics market is evolving rapidly with advancements in both diagnostic and therapeutic technologies. Theranostics, which combines diagnostics and therapy, is becoming increasingly significant in personalized medicine, particularly in oncology. Emerging trends in this market reflect innovations in radiopharmaceutical development, regulatory advancements, and growing applications across various medical conditions. These trends underscore the ongoing shift towards more targeted and effective treatments, enhanced by technological progress and increasing investment in research and development.

• Integration of Targeted Therapies and Diagnostics: The convergence of diagnostic and therapeutic capabilities in radiopharmaceuticals is a key trend. This integration allows for the precise targeting of cancer cells through radiolabeled compounds, improving both diagnosis and treatment. Advances in this area are enhancing the ability to visualize and treat tumors simultaneously, leading to more personalized and effective treatment plans. Companies are developing novel radiopharmaceuticals that can identify specific biomarkers and deliver targeted radiation therapy, significantly improving patient outcomes and reducing side effects.
• Expansion of Radionuclide Options: The market is seeing a diversification of radionuclides used in theranostics, beyond traditional ones like iodine-131. New radionuclides such as lutetium-177 and actinium-227 are gaining prominence due to their advantageous decay properties and effectiveness in treating various cancers. These radionuclides offer improved targeting, better imaging quality, and reduced toxicity. The expansion of radionuclide options is enabling the development of more effective and safer radiopharmaceuticals, broadening the scope of treatable conditions and enhancing therapeutic outcomes.
• Advancements in Radiolabeled Biomolecules: There is growing interest in radiolabeling biomolecules such as antibodies, peptides, and small molecules for theranostic applications. Radiolabeled biomolecules can specifically bind to cancer cells or other disease targets, allowing for highly precise imaging and targeted therapy. Innovations in this area are leading to the development of new radiopharmaceuticals that improve diagnostic accuracy and therapeutic efficacy. Research is focused on optimizing labeling techniques and enhancing the stability and targeting capabilities of these biomolecules, driving forward the field of theranostics.
• Development of Personalized Medicine Approaches: Personalized medicine is increasingly influencing the radiopharmaceutical theranostics market. Tailoring treatments based on individual patient profiles, including genetic and molecular information, is enhancing the precision of theranostics. Advances in genomics and molecular diagnostics are enabling the identification of specific biomarkers that can be targeted with radiopharmaceuticals. This approach ensures that treatments are customized to the patient's unique disease characteristics, improving effectiveness and minimizing adverse effects, and driving the trend towards more individualized treatment strategies.
• Increased Investment and Collaboration: There is a notable increase in investment and collaboration within the radiopharmaceutical theranostics sector. Pharmaceutical companies, biotech firms, and research institutions are partnering to accelerate the development of new radiopharmaceuticals and bring them to market more efficiently. Collaborative efforts are focused on clinical trials, regulatory approvals, and technological advancements. Investment in research and development is fueling innovation, expanding the pipeline of theranostic agents, and enhancing the overall growth of the market. This trend is indicative of the sector's dynamic progress and potential for future breakthroughs.

The radiopharmaceutical theranostics market is undergoing significant transformation driven by advancements in technology and increased investment. Key trends such as the integration of targeted therapies and diagnostics, diversification of radionuclides, development of radiolabeled biomolecules, personalized medicine approaches, and heightened investment and collaboration are reshaping the landscape. These trends reflect the growing emphasis on precision medicine and the potential for more effective and personalized treatments, highlighting the dynamic nature of the radiopharmaceutical theranostics sector.

Recent Developments in the Radiopharmaceutical Theranostics Market

Recent developments in the radiopharmaceutical theranostics market reflect significant strides in combining diagnostic and therapeutic modalities to enhance precision medicine. Theranostics, which merges imaging and targeted therapy, is advancing rapidly due to technological innovations, regulatory progress, and increased focus on personalized treatment approaches. These developments are transforming how diseases, particularly cancer, are diagnosed and treated, leading to more effective and tailored healthcare solutions. Key advancements in this market highlight progress in radionuclide applications, therapeutic agents, and collaborative efforts, which collectively improve patient outcomes and expand the scope of theranostic applications.

• FDA Approvals of New Radiopharmaceuticals: Recent FDA approvals for new radiopharmaceuticals, such as Lutathera for neuroendocrine tumors, mark significant progress in the theranostics market. These approvals signify advancements in targeted radiotherapy, providing more options for personalized cancer treatment. The ability to target specific tumor types with precision reduces off-target effects and improves therapeutic outcomes. The regulatory green light for such agents also facilitates their integration into clinical practice, expanding the availability of advanced treatments for patients and contributing to the growth of the theranostics market.
• Emergence of Novel Radionuclides: The introduction of novel radionuclides, like actinium-227 and copper-64, is enhancing the capabilities of radiopharmaceuticals in theranostics. These radionuclides offer unique decay properties that improve imaging resolution and therapeutic efficacy. For example, actinium-227 is used in targeted alpha therapy, which delivers potent radiation directly to cancer cells. The development and application of these new radionuclides are broadening the therapeutic range and effectiveness of radiopharmaceuticals, supporting the growth of the theranostics market and expanding treatment options.
• Advancements in Radiolabeled Biomolecules: Progress in radiolabeling techniques for biomolecules such as antibodies and peptides is driving innovation in the theranostics market. Radiolabeled biomolecules can specifically target and bind to disease markers, allowing for precise imaging and therapy. Recent advancements include improved labeling methods and the development of novel biomolecules with higher affinity and stability. These advancements enhance the accuracy of diagnostics and the effectiveness of targeted therapies, making radiolabeled biomolecules a key component in personalized medicine and expanding their clinical applications.
• Growth in Personalized Medicine: The shift towards personalized medicine is significantly impacting the radiopharmaceutical theranostics market. Personalized approaches involve tailoring treatments based on individual patient profiles, including genetic and molecular information. This trend is driving the development of theranostics that can precisely target specific biomarkers unique to each patient's disease. By integrating genetic data with radiopharmaceuticals, healthcare providers can offer more effective and individualized treatments, improving patient outcomes and driving the adoption of theranostic solutions.
• Increased Industry Collaboration and Investment: There has been a notable increase in industry collaboration and investment in the radiopharmaceutical theranostics market. Partnerships between pharmaceutical companies, biotech firms, and research institutions are accelerating the development of new theranostic agents and technologies. Collaborative efforts are focused on clinical trials, regulatory approvals, and technological innovations. Increased investment is supporting research and development, leading to the introduction of advanced radiopharmaceuticals and the expansion of theranostic applications. This trend underscores the market's growth potential and the commitment to advancing therapeutic and diagnostic solutions.

Recent developments in the radiopharmaceutical theranostics market highlight significant advancements in targeted therapies and diagnostics. Key developments, including FDA approvals of new agents, emergence of novel radionuclides, advancements in radiolabeled biomolecules, the growth of personalized medicine, and increased collaboration and investment, are driving progress in the field. These advancements are enhancing treatment precision, expanding therapeutic options, and contributing to the overall growth and evolution of the theranostics market, paving the way for more effective and individualized healthcare solutions.

Strategic Growth Opportunities for Radiopharmaceutical Theranostics Market

The radiopharmaceutical theranostics market is evolving rapidly, driven by innovations in diagnostic and therapeutic technologies. Theranostics integrates targeted imaging and treatment, offering promising solutions in precision medicine. As the market grows, several key applications present strategic growth opportunities. These opportunities reflect advancements in oncology, cardiology, neurology, and other areas where theranostics can significantly enhance patient care. By leveraging these applications, stakeholders can drive innovation, improve treatment outcomes, and expand market reach. The following outlines five key growth opportunities across various applications in the radiopharmaceutical theranostics market.

• Oncology: The oncology sector presents a significant growth opportunity in radiopharmaceutical theranostics. The development of targeted therapies using radiopharmaceuticals, such as lutetium-177 and actinium-227, offers precise treatment options for various cancers, including prostate and neuroendocrine tumors. Innovations in radiolabeled antibodies and peptides enable targeted delivery of therapeutic radiation directly to cancer cells, improving treatment efficacy and reducing side effects. Expanding the range of targeted therapies and increasing their accessibility can lead to substantial market growth and enhanced patient outcomes in cancer care.
• Neurology: Neurology is an emerging application area for radiopharmaceutical theranostics. The development of radiopharmaceuticals for neuroimaging and targeted treatment of neurological disorders, such as Alzheimer's disease and Parkinson's disease, represents a significant growth opportunity. New radiotracers and therapeutic agents can enhance the diagnosis and management of these conditions, offering more precise imaging and targeted treatment options. Innovations in this space can improve early diagnosis, monitor disease progression, and tailor therapies to individual patient needs, expanding the market for radiopharmaceutical theranostics in neurology.
• Cardiology: In cardiology, radiopharmaceutical theranostics can revolutionize the diagnosis and treatment of cardiovascular diseases. Advanced radiotracers for cardiac imaging can provide detailed information on myocardial perfusion and function, aiding in the management of conditions such as coronary artery disease. Additionally, targeted radiotherapy could offer new treatment options for heart-related tumors. The development of innovative radiopharmaceuticals for cardiac applications can enhance diagnostic accuracy and therapeutic efficacy, creating substantial growth opportunities in the cardiology segment of the market.
• Infectious Diseases: The application of radiopharmaceuticals in infectious diseases is a growing area of interest. Radiotracers can be used to accurately image and diagnose infections by targeting specific pathogens or inflammatory responses. Additionally, targeted radiotherapy could be explored for treating certain infectious conditions, such as bacterial infections resistant to conventional treatments. Expanding research and development in this area can lead to new diagnostic and therapeutic tools for managing infections, driving growth in the radiopharmaceutical theranostics market and improving patient care.
• Personalized Medicine: Personalized medicine is a key growth opportunity in radiopharmaceutical theranostics. By integrating genetic and molecular information, radiopharmaceuticals can be tailored to target specific biomarkers associated with an individual's disease. This approach enables more precise and effective treatments, enhancing therapeutic outcomes and minimizing side effects. Advancements in genetic profiling and biomarker identification are driving the development of customized theranostic solutions, expanding the market for personalized radiopharmaceuticals and improving the precision of patient care.

Strategic growth opportunities in the radiopharmaceutical theranostics market span several key applications, including oncology, neurology, cardiology, infectious diseases, and personalized medicine. Each application offers unique potential for innovation and expansion, driven by advancements in radiopharmaceutical technologies and their integration into clinical practice. By capitalizing on these opportunities, stakeholders can enhance treatment precision, improve patient outcomes, and drive the continued growth of the theranostics market.

Radiopharmaceutical Theranostics Market Driver and Challenges

The radiopharmaceutical theranostics market is significantly influenced by various technological, economic, and regulatory factors. Major drivers of growth include advancements in radiopharmaceutical technologies, increased demand for personalized medicine, and supportive regulatory environments. Conversely, challenges such as high development costs, regulatory hurdles, and supply chain issues impact market dynamics. Understanding these drivers and challenges is crucial for stakeholders seeking to navigate and capitalize on opportunities within the theranostics sector. This analysis highlights the key factors shaping the market and their implications for future growth.

The factors responsible for driving the radiopharmaceutical theranostics market include:

1. Technological Advancements: Technological advancements in radiopharmaceutical development are a primary driver of the theranostics market. Innovations such as improved radionuclide production, advanced radiolabeling techniques, and enhanced imaging technologies enable more precise and effective diagnostics and therapies. The development of novel radiopharmaceutical agents with better targeting and reduced side effects is expanding treatment options and increasing market demand. These advancements facilitate the creation of personalized treatment plans, ultimately driving market growth by offering more tailored and effective healthcare solutions.

2. Growing Demand for Personalized Medicine: The increasing emphasis on personalized medicine is significantly impacting the radiopharmaceutical theranostics market. Personalized medicine approaches leverage genetic, molecular, and biomarker information to tailor treatments to individual patient profiles. This trend drives the development of theranostic agents that can specifically target unique disease markers, leading to more effective and individualized treatments. As the demand for personalized healthcare solutions grows, so does the need for innovative radiopharmaceuticals, boosting market expansion and encouraging ongoing research and development.

3. Supportive Regulatory Environment: A supportive regulatory environment is a key driver for the growth of the radiopharmaceutical theranostics market. Regulatory agencies, such as the FDA and EMA, have streamlined approval processes for radiopharmaceuticals, providing clearer pathways for bringing new agents to market. Recent regulatory approvals for novel theranostic agents and the establishment of guidelines for clinical trials have facilitated market entry and encouraged investment. This regulatory support helps accelerate the development and commercialization of innovative radiopharmaceuticals, fostering market growth and expanding treatment options.

4. Increased Investment in Research and Development: The rising investment in research and development (R&D) is a significant driver of growth in the theranostics market. Pharmaceutical companies, biotech firms, and research institutions are investing heavily in the development of new radiopharmaceutical agents and technologies. This investment supports the advancement of novel therapies, clinical trials, and technological innovations. Increased R&D funding accelerates the introduction of new theranostic solutions, enhances treatment options, and drives market growth by fostering continuous innovation and expanding the pipeline of available agents.

5. Expanding Applications Across Medical Fields: The expansion of radiopharmaceutical theranostics applications across various medical fields, including oncology, neurology, cardiology, and infectious diseases, is driving market growth. The ability to apply theranostics in diverse therapeutic areas broadens the scope of treatment options and increases market potential. As new indications for radiopharmaceuticals are identified and developed, the market sees increased demand and application of these technologies. This expansion enhances the overall market landscape and provides opportunities for growth across multiple therapeutic domains.

Challenges in the radiopharmaceutical theranostics market are:

1. High Development and Production Costs: High development and production costs pose a significant challenge to the radiopharmaceutical theranostics market. The complex processes involved in producing radiopharmaceuticals, including radionuclide production, radiolabeling, and quality control, require substantial financial investment. These high costs can limit the accessibility of new theranostic agents and create barriers for smaller companies entering the market. Addressing these cost challenges is essential for ensuring broader market adoption and maintaining the sustainability of the sector.

2. Regulatory Hurdles and Approval Processes: Navigating regulatory hurdles and approval processes can be challenging for companies in the radiopharmaceutical theranostics market. The stringent requirements for clinical trials, safety assessments, and regulatory approvals can delay market entry and increase development timelines. Differences in regulatory standards across regions can further complicate the approval process. Companies must effectively manage these regulatory challenges to successfully bring new theranostic agents to market and ensure compliance with global standards.

3. Supply Chain and Distribution Issues: Supply chain and distribution issues can impact the availability and market growth of radiopharmaceuticals. The production and distribution of radiopharmaceuticals are often complex due to the need for specialized handling and storage conditions. Any disruptions in the supply chain, such as delays in radionuclide production or logistical challenges, can affect the timely delivery of products to healthcare providers. Addressing these supply chain challenges is crucial for ensuring consistent product availability and meeting market demand.

The radiopharmaceutical theranostics market is driven by multiple factors such as technological development, increasing demand for targeted therapies, favorable market policies, increased funding for R & D, and more wide-ranging uses within medicine. However, there are significant barriers such as high costs of development, regulatory difficulties, and supply chain difficulties that must be taken into account. In any case, some of these issues must be accommodated in order for the market to further develop and prosper under the view of the parties involved that aim to capitalize on the available prospects and counter the challenges that exist in the dynamic landscape of the theranostics market.

List of Radiopharmaceutical Theranostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiopharmaceutical theranostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiopharmaceutical theranostics companies profiled in this report include-

• Bayer
• GE Healthcare Technologies
• Curium
• Lantheus Medical Imaging
• Telix Pharmaceuticals
• Cardinal Health
• Advanced Accelerator Applications
• Jubilant Radiopharma
• Theragnostics
• Nuview Life Sciences

Radiopharmaceutical Theranostics by Segment

The study includes a forecast for the global radiopharmaceutical theranostics by product type, source, indication, end use, and region.

Radiopharmaceutical Theranostics Market by Product Type [Analysis by Value from 2018 to 2030]:

• Alpha Emitters
• Beta Emitters
• PET Tracers

Radiopharmaceutical Theranostics Market by Source [Analysis by Value from 2018 to 2030]:

• Nuclear Reactors
• Cyclotrons

Radiopharmaceutical Theranostics Market by Indication [Analysis by Value from 2018 to 2030]:

• Oncology
• Cardiology
• Neurology
• Others

Radiopharmaceutical Theranostics Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Diagnostic Imaging Centers
• Academic & Research Institutes
• Others

Radiopharmaceutical Theranostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Radiopharmaceutical Theranostics Market

The radiopharmaceutical theranostics market is witnessing significant advancements as the integration of diagnostics and therapeutic approaches transforms cancer treatment and personalized medicine. Recent developments in this market across key regions-including the United States, China, Germany, India, and Japan-reflect progress in targeted therapies, innovative radiopharmaceuticals, and enhanced clinical applications. These developments underscore the growing importance of precision medicine in improving patient outcomes and optimizing treatment efficacy. Here's a look at recent developments in these key markets:

• United States: In the United States, the radiopharmaceutical theranostics market is experiencing rapid growth driven by the advancement of targeted therapies and precision medicine. Key developments include the FDA's approval of new radiopharmaceuticals such as Lutathera for neuroendocrine tumors and the expansion of radioligand therapy options. The integration of imaging and therapeutic capabilities is enhancing the ability to diagnose and treat cancer more precisely. Significant investment in research and clinical trials, along with collaborations between pharmaceutical companies and research institutions, is accelerating innovation and broadening the scope of theranostic applications in the U.S.
• China: China radiopharmaceutical theranostics market is expanding as the country invests heavily in biotechnology and healthcare infrastructure. Recent developments include advancements in the production and application of radiopharmaceuticals for cancer treatment, with a focus on developing domestic manufacturing capabilities and clinical trials. China is also increasing its efforts in personalized medicine, with several new theranostic agents undergoing trials to improve the accuracy of diagnosis and treatment. The Chinese government's support for innovation and healthcare reforms is driving the adoption of advanced radiopharmaceutical technologies, contributing to significant market growth.
• Germany: Germany is at the forefront of innovation in the radiopharmaceutical theranostics market, with a strong emphasis on research and development. Recent advancements include the introduction of new radiopharmaceutical agents and therapies, such as targeted radiotherapy for prostate cancer. Germany's robust healthcare system and collaboration between academic institutions and industry are fostering advancements in theranostics. Additionally, the country is focusing on integrating advanced imaging techniques with radiopharmaceutical therapies to enhance diagnostic accuracy and treatment efficacy. Germany leadership in clinical trials and regulatory approvals is positioning it as a key player in the global market.
• India: India radiopharmaceutical theranostics market is growing as the country enhances its healthcare infrastructure and investment in medical technologies. Recent developments include the introduction of new radiopharmaceutical products and increasing access to advanced therapies in both urban and rural areas. Indian research institutions and pharmaceutical companies are actively involved in developing and testing novel theranostic agents. The government's initiatives to improve cancer care and increase the availability of advanced diagnostic and therapeutic options are driving growth in the market. India's focus on expanding its capabilities in radiopharmaceutical production and clinical research is contributing to the sector's advancement.
• Japan: Japan is making significant strides in the radiopharmaceutical theranostics market, particularly in the development and application of novel radiopharmaceutical agents. Recent advancements include the approval of new theranostic agents for targeted cancer therapies and improvements in imaging technologies. Japan strong emphasis on research and collaboration between universities and industry is fostering innovation in the market. Additionally, the country is focused on integrating theranostic approaches into its healthcare system to enhance precision medicine. Japan advancements in radiopharmaceutical production and clinical applications are driving growth and positioning it as a key player in the global market.

Features of the Global Radiopharmaceutical Theranostics Market

Market Size Estimates: Radiopharmaceutical theranostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radiopharmaceutical theranostics market size by various segments, such as by product type, source, indication, end use, and region in terms of value ($B).

Regional Analysis: Radiopharmaceutical theranostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, sources, indications, end uses, and regions for the radiopharmaceutical theranostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiopharmaceutical theranostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the radiopharmaceutical theranostics market size?

Answer: The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030.

Q.2 What is the growth forecast for radiopharmaceutical theranostics market?

Answer: The global radiopharmaceutical theranostics market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the radiopharmaceutical theranostics market?

Answer: The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

Q4. What are the major segments for radiopharmaceutical theranostics market?

Answer: The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets.

Q5. Who are the key radiopharmaceutical theranostics market companies?

Answer: Some of the key radiopharmaceutical theranostics companies are as follows:

• Bayer
• GE Healthcare Technologies
• Curium
• Lantheus Medical Imaging
• Telix Pharmaceuticals
• Cardinal Health
• Advanced Accelerator Applications
• Jubilant Radiopharma
• Theragnostics
• Nuview Life Sciences

Q6. Which radiopharmaceutical theranostics market segment will be the largest in future?

Answer: Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Q7. In radiopharmaceutical theranostics market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radiopharmaceutical theranostics market by product type (alpha emitters, beta emitters, and PET tracers), source (nuclear reactors and cyclotrons), indication (oncology, cardiology, neurology, and others), end use (hospitals, diagnostic imaging centers, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Radiopharmaceutical Theranostics Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Radiopharmaceutical Theranostics Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Radiopharmaceutical Theranostics Market by Product Type
  • 3.3.1: Alpha Emitters
  • 3.3.2: Beta Emitters
  • 3.3.3: PET Tracers
• 3.4: Global Radiopharmaceutical Theranostics Market by Source
  • 3.4.1: Nuclear Reactors
  • 3.4.2: Cyclotrons
• 3.5: Global Radiopharmaceutical Theranostics Market by Indication
  • 3.5.1: Oncology
  • 3.5.2: Cardiology
  • 3.5.3: Neurology
  • 3.5.4: Others
• 3.6: Global Radiopharmaceutical Theranostics Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Diagnostic Imaging Centers
  • 3.6.3: Academic & Research Institutes
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Radiopharmaceutical Theranostics Market by Region
• 4.2: North American Radiopharmaceutical Theranostics Market
  • 4.2.1: North American Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
  • 4.2.2: North American Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
• 4.3: European Radiopharmaceutical Theranostics Market
  • 4.3.1: European Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
  • 4.3.2: European Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
• 4.4: APAC Radiopharmaceutical Theranostics Market
  • 4.4.1: APAC Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
  • 4.4.2: APAC Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
• 4.5: ROW Radiopharmaceutical Theranostics Market
  • 4.5.1: ROW Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
  • 4.5.2: ROW Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Source
  • 6.1.3: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Indication
  • 6.1.4: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by End Use
  • 6.1.5: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Region
• 6.2: Emerging Trends in the Global Radiopharmaceutical Theranostics Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radiopharmaceutical Theranostics Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiopharmaceutical Theranostics Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Bayer
• 7.2: GE HealthCare Technologies
• 7.3: Curium
• 7.4: Lantheus Medical Imaging
• 7.5: Telix Pharmaceuticals
• 7.6: Cardinal Health
• 7.7: Advanced Accelerator Applications
• 7.8: Jubilant Radiopharma
• 7.9: Theragnostics
• 7.10: NuView Life Sciences